Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fibrate pharmacogenomics: expanding past the genome.

Pharmacogenomics - 1 Mar 2020

House John S, Motsinger-Reif Alison A

Abstract excerpt

Fibrates are a medication class prescribed for decades as 'broad-spectrum' lipid-modifying agents used to lower blood triglyceride levels and raise high-density lipoprotein cholesterol levels. Such lipid changes are associated with a decrease in cardiovascular disease, and fibrates are commonly used to reduce risk of dangerous cardiovascular outcomes. As with most drugs, it is well established that response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Diseases
Share to Genome
Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypolipidemic Agents

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Risk Factors

Share to Triglycerides

Source

Open in PubMed Open full text

Identifiers

PMID: 32180510
DOI: 10.2217/pgs-2019-0140
PMCID: PMC7202259

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fibrate pharmacogenomics: expanding past the genome.PMID 32180510Read ↗

A treasure of pharmacogenomic insights into postprandial lipoproteinemia and therapeutic responses to fibrate therapy: lessons from GOLDN.Semantic proximity Read ↗

Pharmacogenomics in Cardiovascular Diseases.Semantic proximity Read ↗

Pharmacogenomics in Hypertension: Where We Stand TodaySemantic proximity Read ↗

Pharmacogenomics of cholesterol-lowering therapy.Semantic proximity Read ↗

Pharmacogenomics, lipid disorders, and treatment options.Semantic proximity Read ↗

Pharmacogenomics in clinical practice and drug development.Semantic proximity Read ↗

Recent development in pharmacogenomics: from candidate genes to genome-wide association studies.Semantic proximity Read ↗

[Cardiovascular pharmacogenomics].Semantic proximity Read ↗

Pharmacogenomic approaches to study the effects of antihypertensive drugs.Semantic proximity Read ↗

Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension?Semantic proximity Read ↗

Use of pharmacogenomics in elderly patients treated for cardiovascular diseasesSemantic proximity Read ↗

A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.